MANILA, Philippines — Replicating the four-page voter information sheet (VIS) for the May 2025 elections will be impossible despite its simple layout, Commission on Elections (Comelec) Chairman George ...

7,8 To demonstrate LNP–mRNA MAQ by FFF–MALS, the size, particle concentration, molar mass, and mRNA drug substance distributions of the Comirnaty and Spikevax bivalent vaccines against the ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid nanoparticles to develop its SpikeVax COVID-19 vaccine. NU had a critical role ...

According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

Moderna earned $6.7 billion in revenue from Spikevax last year. Pfizer made $11.2 billion from sales of Comirnaty, the COVID vaccine it developed with German partner BioNTech. Sales of both ...

Spikevax. A consistent trend was seen in a subset of adults age 65 and older, the company said in a statement. Back To Top ...

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and ...

At the moment, Moderna's Spikevax vaccine for Covid-19 is used in the NHS booster programmes, alongside Pfizer/BioNTech's Comirnaty. A newer version of Spikevax has been created and tested by ...

Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 ...